IPCA Laboratories reported a 32.5% year-on-year increase in consolidated net profit to ₹375 crore for the September quarter, compared with ₹283 crore in the corresponding period last year. Revenue from operations grew 13.8% to ₹2,910 crore in Q2 FY27 from ₹2,557 crore a year ago, according to the company's exchange filing.
Operating performance was stronger, with earnings before interest, tax, depreciation and amortisation rising 23.7% year-on-year to ₹674 crore from ₹545 crore. EBITDA margin expanded to 23% from 21% in the year-ago quarter. Domestic formulations income increased 14% year-on-year to ₹1,157.20 crore during the quarter.

Export income also recorded healthy growth, rising 17% to ₹951.39 crore, according to the company's filing. The company's filing also disclosed exceptional items relating to its subsidiary, Unichem Laboratories, including a provision towards a legal claim in the UK.
Unichem recognises provision for UK legal claimUnichem Laboratories and its subsidiary Niche Generics have recognised a provision of £1.9 million, equivalent to approximately ₹24.26 crore, towards a legal claim in the UK involving the drug perindopril.

Laboratoires Servier had filed a claim against Niche Generics and Unichem, among others, seeking a contribution towards damages claimed by UK health authorities in the perindopril proceedings. According to the filing, Niche Generics intends to resolve the matter at the earliest, including through a possible compromise.
The provision has been recognised as an exceptional item in the consolidated results for the quarter and half year ended September 30, 2026. The filing also detailed an exceptional gain recorded in the previous financial year following the sale of Unichem Laboratories' freehold land and building at Prabhat Estate in Jogeshwari , Mumbai.

Unichem had entered into an agreement with Lodha Developers, formerly known as Macrotech Developers, on October 9, 2025, to sell the property for ₹279 crore. The transaction resulted in a gain of ₹17.65 crore, net of related expenses, which was recognised as an exceptional item during the previous year.
Shares of IPCA Laboratories were trading 1.17% lower at ₹1,949 on the NSE at around 2:34 pm on Thursday. The stock has declined 0.4% over the past month but has gained around 39% so far in 2026.